分析NK-1受体对抗剂的不良事件:来自FAERS数据库的药监测研究
Hong Pan1, Xiang Shi2, Yiguo Jiang3
1Department of Pharmacy, Wuxi No. 5 People's Hospital, Wuxi, 214007, China.
Scientific reports
|December 29, 2024
概括
这项研究分析了NK-1受体对抗剂 (NK-1RAs) 的现实不良事件,发现了可变的安全性概况,并确定了诸如脑病变和内分泌疾病等新风险. 临床医生应密切监测这些NK-1RA副作用.
科学领域:
- 药物监督 药物监督 药物监督
- 临床药理学 临床药理学
- 瘤学 支持性护理 支持性护理
背景情况:
- 神经基因-1受体对抗剂 (NK-1RAs) 有效地预防化疗诱导的恶心和吐 (CINV).
- 对于NK-1RAs的现实安全数据仍然不完全表征.
- 这项研究旨在系统地分析与NK-1RAs相关的不良事件 (AE).
研究的目的:
- 研究和比较不同NK-1受体对抗剂的不良事件概况.
- 识别与NK-1RA使用相关的潜在安全信号和以前未被识别的不良事件.
- 为临床医生管理NK-1RA患者提供现实世界的安全见解.
主要方法:
- 利用FAERS数据库 (2009年第一季度 - 2023年第四季度) 来获取不良事件数据.
- 雇佣了不成比例的分析,包括ROR,PRR,BCPNN和MGPS.
- 分析了5434份AE报告,其中NK-1RAs是主要的疑似药物.
主要成果:
- 在各种系统器官类 (SOC) 中确定了重要的安全信号.
- 常见的副作用包括一般性疾病和注射部位反应 (aprepitant, fosaprepitant).
- 在内分泌疾病中检测到毒性脑病变和新信号 (例如,SIADH,上腺功能不充分,低血症).
结论:
- NK-1RA安全概况表现出变化,注射部位反应对静脉注射配方是一种担忧.
- 密切监测脑病变,特别是阿普雷皮坦和伊福斯法米德,至关重要.
- 临床医生必须警新发现的高风险副作用,如不适当的抗利尿激素分泌,上腺功能不足和低血症.
相关概念视频
01:19Pharmacovigilance
730
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
730
01:25Drug Regulation
1.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.2K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
131
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
131
01:20Antiepileptic Drugs: Potassium Channel Activators
118
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
118
01:11Clinical Trials: Overview
2.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.4K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
299
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
299